PubRank

Napoleone Ferrara

Author PubWeight™ 278.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 49.02
2 VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008 9.87
3 HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003 9.12
4 Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007 7.37
5 Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007 6.76
6 Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003 6.44
7 Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006 4.77
8 Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003 4.56
9 Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002 4.46
10 VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002 4.10
11 The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003 3.89
12 PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009 3.71
13 Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007 3.70
14 Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2005 3.30
15 Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004 3.28
16 VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002 3.27
17 The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell 2006 3.10
18 The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell 2009 3.08
19 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005 3.00
20 An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013 3.00
21 Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010 2.93
22 Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011 2.83
23 Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 2010 2.77
24 Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006 2.75
25 G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009 2.68
26 Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013 2.64
27 Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010 2.64
28 Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest 2012 2.58
29 Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 2003 2.56
30 VEGFA is necessary for chondrocyte survival during bone development. Development 2004 2.54
31 CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood 2012 2.43
32 Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005 2.38
33 Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008 2.30
34 Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol 2003 2.24
35 VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004 2.22
36 Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012 2.21
37 Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006 2.10
38 Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008 2.08
39 ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem 2002 2.02
40 A direct and melanopsin-dependent fetal light response regulates mouse eye development. Nature 2013 1.98
41 Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development 2005 1.93
42 Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 2011 1.91
43 Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012 1.90
44 Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 2012 1.79
45 The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A 2003 1.78
46 VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2008 1.76
47 PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010 1.75
48 Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A 2004 1.75
49 Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007 1.73
50 Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 2009 1.72
51 Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 2004 1.71
52 Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 2010 1.70
53 Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005 1.64
54 Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2012 1.63
55 Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008 1.63
56 Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004 1.62
57 Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009 1.58
58 Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009 1.56
59 Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 2004 1.55
60 The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl) 2002 1.54
61 Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol 2007 1.51
62 Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008 1.51
63 Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 2012 1.30
64 Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 2006 1.29
65 Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2006 1.29
66 Antiangiogenic therapy for cancer: an update. Cancer J 2007 1.27
67 Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A 2011 1.26
68 Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A 2013 1.25
69 Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008 1.23
70 Endothelium-microenvironment interactions in the developing embryo and in the adult. Dev Cell 2007 1.22
71 Characterization and regulation of bv8 in human blood cells. Clin Cancer Res 2009 1.21
72 Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J Biol Chem 2001 1.20
73 Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest Ophthalmol Vis Sci 2008 1.19
74 Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002 1.16
75 The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf. Development 2009 1.16
76 Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol 2012 1.15
77 Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002 1.14
78 The heart endocardium is derived from vascular endothelial progenitors. Development 2011 1.13
79 Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech 2010 1.13
80 Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 2012 1.11
81 Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PLoS One 2010 1.11
82 A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010 1.10
83 Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A 2007 1.10
84 Vascular endothelial growth factor co-ordinates proper development of lung epithelium and vasculature. Mech Dev 2005 1.10
85 S1P1 inhibits sprouting angiogenesis during vascular development. Development 2012 1.08
86 Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife 2013 1.06
87 Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun 2011 1.03
88 Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 2013 1.02
89 VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. EMBO Mol Med 2013 1.00
90 VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. Am J Physiol Regul Integr Comp Physiol 2002 0.99
91 Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. Am J Pathol 2010 0.98
92 Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J Biol Chem 2012 0.98
93 Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 2007 0.98
94 Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 2008 0.97
95 Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 2004 0.92
96 EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. Trends Cardiovasc Med 2003 0.91
97 Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci Signal 2013 0.91
98 Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology 2003 0.90
99 Macrophage Wnt-Calcineurin-Flt1 signaling regulates mouse wound angiogenesis and repair. Blood 2013 0.90
100 Quantification of viable tumor microvascular characteristics by multispectral analysis. Magn Reson Med 2008 0.90
101 Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. Exp Cell Res 2003 0.90
102 Crim1 maintains retinal vascular stability during development by regulating endothelial cell Vegfa autocrine signaling. Development 2013 0.89
103 Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm 2014 0.88
104 Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood 2005 0.88
105 Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. Microcirculation 2004 0.87
106 Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. Neoplasia 2013 0.87
107 Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res 2013 0.86
108 Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. PLoS One 2010 0.86
109 From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol 2011 0.84
110 Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. J Clin Endocrinol Metab 2004 0.84
111 The function of VEGF-A in lens development: formation of the hyaloid capillary network and protection against transient nuclear cataracts. Exp Eye Res 2008 0.84
112 Vegf regulates embryonic erythroid development through Gata1 modulation. Blood 2010 0.83
113 Vascular targeting via caveolae. Nat Biotechnol 2007 0.83
114 EG-VEGF: a novel mediator of endocrine-specific angiogenesis, endothelial phenotype, and function. Ann N Y Acad Sci 2004 0.83
115 Loss of vascular endothelial growth factor A (VEGFA) isoforms in the testes of male mice causes subfertility, reduces sperm numbers, and alters expression of genes that regulate undifferentiated spermatogonia. Endocrinology 2013 0.83
116 Imaging tumor angiogenesis. J Clin Invest 2006 0.83
117 Inhibiting the response to VEGF in diabetes. Sci Signal 2014 0.81
118 Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. 1989. Biochem Biophys Res Commun 2012 0.80
119 Paracrine VEGF/VE-cadherin action on ovarian cancer permeability. Exp Biol Med (Maywood) 2006 0.80
120 EG-VEGF and the concept of tissue-specific angiogenic growth factors. Semin Cell Dev Biol 2002 0.79
121 Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors. Methods Enzymol 2008 0.79
122 Multiple effects of angiopoietin-2 blockade on tumors. Cancer Cell 2011 0.79
123 Targeting the tumor microenvironment with SRC kinase inhibition. Clin Cancer Res 2010 0.79
124 Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells. Cardiovasc Diabetol 2015 0.75
125 Anti-angiogenic drugs to treat human disease: an interview with Napoleone Ferrara by Kristin H. Kain. Dis Model Mech 2009 0.75
126 Napoleone Ferrara discusses Avastin and the future of anti-angiogenesis therapy. Interview by Ulrike Knies-Bamforth and Christopher Watson. Drug Discov Today 2005 0.75
127 VEGF modulates synaptic activity in the developing spinal cord. Dev Neurobiol 2014 0.75
128 Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity. Cell 2016 0.75
129 A message from the new editor-in-chief. Mol Cancer Ther 2014 0.75
130 A conversation with Napoleone Ferrara. J Clin Invest 2014 0.75